A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

NCT06973291 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

606

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Zasocitinib
DRUG: Deucravacitinib
DRUG: Placebo to match zasocitinib
DRUG: Placebo to match deucravacitinib

Sponsor

Takeda